Medico-economic Evaluation of Therapeutic Adaptation Guided by the Soluble Suppression of Tumorigenicity 2 (sST-2) Biomarker in the Management of Patients With Acute Heart Failure
Recruiting · NCT04554277 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Montpellier
View the official record on ClinicalTrials.gov →Interventions studied
Biomarker guided therapy
What this trial is about
Management of patients with heart Failure remains a major health concern because of the high rate of rehospitalization, mortality and induced-cost. Biomarkers could help to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. As a working hypothesis, we postulate that sST2 values monitoring could be an helpful guide for medical management in an attempt to reduce hospital readmission.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- 18 years or older
- Hospitalization for heart failure (NTproBNP(N-terminal pro-Brain Natriuretic Peptid) ≥450 pg/ml (ou BNP ≥400 pg/ml)
Exclusion criteria
- Waiting for heart transplantation
- Scheduled valve surgery
- No fluent french
- Not able to provide informed consent
- Hemodynamic instability
- Poor outcome during the first week.
- Pregnancy
- Participating to other study
Where it is running
12 locations listed.
- CHU Angers - Angers, France
- CHU Besançon - Besançon, France
- CH Béziers - Béziers, France
- CHU Caen - Caen, France
- CHU Grenoble - Grenoble, France
- Arnaud de Villeneuve Hospital - Montpellier, France
- CHU Nimes - Nîmes, France
- APHP Pompidou - Paris, France
- CHU Rennes - Rennes, France
- CHU Toulouse - Toulouse, France
- CHU Vannes - Vannes, France
- Lapeyronie Hospital - Montpellier, Occitanie, France